2017 Corporate Performance Objectives
|
Total Base
and Bonus
Points
|
Total Base and Bonus Points Achieved
|
Research and Development Objectives
|
|
|
Clinical Objectives
|
|
|
•
|
Delivery of top-line results for primary endpoint in Phase 2 clinical trial of MGL-3916 in NASH
|
30
|
45 (150% achievement of target)
|
•
|
Delivery of top-line results for key secondary endpoints in Phase 2 clinical trial of MGL-3916 in NASH
|
20
|
20 (100% achievement of target)
|
•
|
Delivery of top-line results for primary endpoint in Phase 2 clinical trial of MGL-3916 in HeFH
|
20
|
20 (100% achievement of target)
|
•
|
Delivery of top-line results for key secondary endpoints in Phase 2 clinical trial of MGL-3916 in HeFH
|
7.5
|
0 (less than 75% achievement of target)
|
Other Research and Development Objectives
|
|
|
•
|
Manufacture of drug product for Phase 3 clinical trials
|
7
|
10.5 (150% achievement of target)
|
•
|
Development and selection of Phase 3 drug product formulation
|
5
|
5 (100% achievement of target)
|
•
|
Achievement of ancillary animal and human studies of MGL-3196 and Metabolite
|
8
|
12 (150% achievement of target)
|
•
|
Development of commercial quality drug product
|
5
|
5 (100% achievement of target)
|
•
|
Ancillary FDA submissions
|
5
|
0 (less than 75% achievement of target)
|
Finance Objectives
|
|
|
•
|
Achievement of financing objectives
|
15
|
22.5 (150% achievement of target)
|
•
|
Achievement of financing objectives with blended discount to market price less than specified percentage
|
5
|
5 (100% achievement of target)
|
•
|
Manage operating expenditures in accordance with Board approved operating plan
|
7.5
|
11.25 (150% achievement of target)
|
Corporate Development Objectives
|
|
|
•
|
Milestones relating to investor/analyst meetings
|
2.5
|
3.75 (150% achievement of target)
|
•
|
Milestones relating to analyst coverage
|
5
|
7.5 (150% achievement of target)
|
Total
|
142.5
|
167.5
|
